A cell-based model of coagulation and the role of factor VIIa, Blood Reviews, vol.17, pp.1-5, 2003. ,
DOI : 10.1016/S0268-960X(03)90000-2
What Does It Take to Make the Perfect Clot?, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.1, pp.41-49, 2006. ,
DOI : 10.1161/01.ATV.0000193624.28251.83
Blood coagulation, Biochemistry (Moscow), vol.67, issue.1, pp.3-12, 2002. ,
DOI : 10.1023/A:1013985911759
Serpins in thrombosis, hemostasis and fibrinolysis, Journal of Thrombosis and Haemostasis, vol.262, issue.Suppl. 3, pp.102-117, 2007. ,
DOI : 10.1016/S1570-9639(03)00164-X
Physiologie et régulation cellulaire du système de la protéine C ,
Physiologie de la coagulation ,
Activated protein C, Journal of Thrombosis and Haemostasis, vol.234, pp.73-80, 2007. ,
DOI : 10.4049/jimmunol.165.8.4697
L'inhibiteur de la voie du facteur tissulaire (TFPI), molécule clé de défense contre la thrombose, Sang Thrombose Vaisseaux, vol.11, pp.548-554, 1999. ,
Principles and rules for their use . Dosage of nonfractionated heparins], Rev Prat, vol.48, pp.1361-1366, 1998. ,
Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI), Thrombosis Research, vol.50, issue.6, pp.803-816, 1988. ,
DOI : 10.1016/0049-3848(88)90340-4
Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate, Circulation, vol.95, issue.1, pp.118-142, 1997. ,
DOI : 10.1161/01.CIR.95.1.118
Existe-t-il des différences entre les héparines de bas poids moléculaire ? San g Thrombose Vaisseaux, pp.6-10, 2006. ,
Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004. ,
DOI : 10.1378/chest.126.3_suppl.188S
BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE, Thrombosis Research, vol.86, issue.1, pp.1-36, 1997. ,
DOI : 10.1016/S0049-3848(97)00042-X
Low-Molecular-Weight Heparins: Are they all the Same?, British Journal of Haematology, vol.86, issue.1, pp.12-20, 2003. ,
DOI : 10.1302/0301-620X.82B6.9869
Antithrombotic Therapy for Venous Thromboembolic Disease, Chest, vol.126, issue.3, pp.401-428, 2004. ,
DOI : 10.1378/chest.126.3_suppl.401S
Low molecular weight heparins: are they interchangeable? No, Journal of Thrombosis and Haemostasis, vol.86, issue.Suppl., pp.12-15, 2003. ,
DOI : 10.1016/S0049-3848(00)00272-3
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1538-7836.2003.00017.x/pdf
Low molecular weight heparins: are they interchangeable? Yes, Journal of Thrombosis and Haemostasis, vol.100, issue.Suppl. 1, pp.10-11, 2003. ,
DOI : 10.1056/NEJM199204093261502
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1538-7836.2003.00014.x/pdf
Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.355, issue.3, pp.596-603, 2003. ,
DOI : 10.1016/S0140-6736(00)02324-2
Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.40, issue.3, p.598, 2003. ,
DOI : 10.1016/S0735-1097(02)02336-7
Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.162, issue.3, pp.599-600, 2003. ,
DOI : 10.1001/archinte.162.16.1833
Low-molecular-weight heparins: pharmacologic profile and product differentiation, The American Journal of Cardiology, vol.82, issue.5, p.3, 199810. ,
DOI : 10.1016/S0002-9149(98)00105-2
Why differentiate low molecular weight heparins for venous thromboembolism?, Thrombosis Journal, vol.5, issue.1, p.8, 2007. ,
DOI : 10.1186/1477-9560-5-8
Factor Xa Inhibition: Correlation between the Plasma Levels of Anti-Xa Activity and Occurrence of Thrombosis and Haemorrhage, Pathophysiology of Haemostasis and Thrombosis, vol.23, issue.1, pp.89-98, 1993. ,
DOI : 10.1159/000216915
Treatment doses of different low-molecular weight heparins and unfractioneated heparins differ in their anticoagulating effects in respect to aptt, hep test , anti-iia-and anti-xa-activity, Lab Med, vol.16, pp.174-177, 1992. ,
Héparine non fractionnée et héparines de bas poids moléculaire, Samama MM et collaborateurs eds. H émorragies et thromboses. Du diagnostic au traitement Paris: Masson, pp.294-304, 2004. ,
Difficultés et pièges de la surveillance des traitements par l'héparine, Sang Thrombose Vaisseaux, vol.15, pp.131-135, 2003. ,
Fareed 1. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent, Expert Opin Investig Drugs, vol.II, pp.397-407, 2002. ,
The calibrated automated thrombogram (CAT): a universal routine test for hyperand hypocoagulability, Pathophysiol Haemost Thromb, vol.32, pp.249-53, 2002. ,
The measurement and application of thrombin generation, British Journal of Haematology, vol.77, issue.5, pp.653-61, 2005. ,
DOI : 10.1046/j.1538-7836.2003.00450.x
Bemiparin, Drugs, vol.88, issue.1, pp.2357-2377, 2003. ,
DOI : 10.2165/00003495-200363210-00009
Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation, Journal of Thrombosis and Haemostasis, vol.69, issue.5, pp.955-62, 2007. ,
DOI : 10.1159/000073609
The effect of different anticoagulants on thrombin generation, Blood Coagulation & Fibrinolysis, vol.17, issue.2, pp.131-137, 2006. ,
DOI : 10.1097/01.mbc.0000214708.73374.ce
Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time, Journal of Thrombosis and Haemostasis, vol.71, issue.8, pp.1395-401, 2004. ,
DOI : 10.1080/00313020120062974
Inhibition of thrombin generation by heparin and 10w molecular weight (LMW) heparins in the absence and presence of platelet factor 4, Br J, vol.82, pp.406-413, 1992. ,
ATiII as a rate limiting factor for the measurement of pentasaccharide in laboratory assays, Thromb Haemost, vol.65, p.1314, 1991. ,
Pharmacokinetics and tolerance of the natural pentasaccharide (SR90 107/0RG31540) with high affinity to antithrombin III in man, Thromb Haemost, vol.74, pp.1468-1473, 1995. ,
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, Journal of Thrombosis and Haemostasis, vol.27, issue.4, pp.886-888, 2007. ,
DOI : 10.1111/j.1538-7836.2005.01657.x
Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex, Journal of Thrombosis and Haemostasis, vol.36, issue.6, pp.1258-63, 2003. ,
DOI : 10.1021/bi970979+
Anticoagulant mechanism of actions of low molecular weight heparins In: Doutremepuich C ed. Low molecular weight heparins in clinical practice, pp.23-50, 1992. ,
Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight, Journal of Thrombosis and Haemostasis, vol.122, issue.1, pp.83-92, 2006. ,
DOI : 10.1161/01.cir.0000089185.80318.3f
Current phannacogenetic developments in oral anticoagulation therapy: The influence of variant VKORCI and CYP2C9 alleles, Thromb Haemost, vol.98, pp.570-578, 2007. ,
Genetic factors underlying differential blood platelet sensitivity to inhibitors, Pharmacol Rep, vol.57, pp.1-13, 2005. ,
Pharmacog??n??tique et m??dicaments antiplaquettaires, La Revue de M??decine Interne, vol.26, issue.9, pp.725-757, 2005. ,
DOI : 10.1016/j.revmed.2005.02.006
Development of Generic Low Molecular Weight Heparins: A Perspective, Hematology/Oncology Clinics of North America, vol.19, issue.1, pp.53-68, 2005. ,
DOI : 10.1016/j.hoc.2004.09.005